These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30638319)

  • 21. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
    Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Substantia nigra hyperechogenicity and Parkinson's disease risk in patients with essential tremor.
    Sprenger FS; Wurster I; Seppi K; Stockner H; Scherfler C; Sojer M; Schmidauer C; Berg D; Poewe W
    Mov Disord; 2016 Apr; 31(4):579-83. PubMed ID: 26893155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
    Hill WD; Arai M; Cohen JA; Trojanowski JQ
    J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging.
    Anglade P; Vyas S; Hirsch EC; Agid Y
    Histol Histopathol; 1997 Jul; 12(3):603-10. PubMed ID: 9225140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Substantia nigra tangles are related to gait impairment in older persons.
    Schneider JA; Li JL; Li Y; Wilson RS; Kordower JH; Bennett DA
    Ann Neurol; 2006 Jan; 59(1):166-73. PubMed ID: 16374822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Longitudinal changes in free-water within the substantia nigra of Parkinson's disease.
    Ofori E; Pasternak O; Planetta PJ; Li H; Burciu RG; Snyder AF; Lai S; Okun MS; Vaillancourt DE
    Brain; 2015 Aug; 138(Pt 8):2322-31. PubMed ID: 25981960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential Alterations in Metabolism and Proteolysis-Related Proteins in Human Parkinson's Disease Substantia Nigra.
    Grünblatt E; Ruder J; Monoranu CM; Riederer P; Youdim MB; Mandel SA
    Neurotox Res; 2018 Apr; 33(3):560-568. PubMed ID: 29218503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parkinson's disease without nigral degeneration: a pathological correlate of scans without evidence of dopaminergic deficit (SWEDD)?
    Ling H; Kearney S; Yip HL; Silveira-Moriyama L; Revesz T; Holton JL; Strand C; Davey K; Mok KY; Polke JM; Lees AJ
    J Neurol Neurosurg Psychiatry; 2016 Jun; 87(6):633-41. PubMed ID: 26209716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of striatonigral connectivity using probabilistic tractography in Parkinson's disease.
    Theisen F; Leda R; Pozorski V; Oh JM; Adluru N; Wong R; Okonkwo O; Dean DC; Bendlin BB; Johnson SC; Alexander AL; Gallagher CL
    Neuroimage Clin; 2017; 16():557-563. PubMed ID: 28971007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Age and gender differences in behavioral and morphological outcome after 6-hydroxydopamine-induced lesion of the substantia nigra in rats.
    Tamás A; Lubics A; Szalontay L; Lengvári I; Reglodi D
    Behav Brain Res; 2005 Mar; 158(2):221-9. PubMed ID: 15698888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Iron, the substantia nigra and related neurological disorders.
    Snyder AM; Connor JR
    Biochim Biophys Acta; 2009 Jul; 1790(7):606-14. PubMed ID: 18778755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuronal loss in the substantia nigra in patients with Alzheimer's disease and Parkinson's disease in relation to extrapyramidal symptoms and dementia.
    Rinne JO; Rummukainen J; Paljärvi L; Säkö E; Mölsä P; Rinne UK
    Prog Clin Biol Res; 1989; 317():325-32. PubMed ID: 2602422
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The ultra early diagnosis of Parkinson's disease by the enhanced substantia nigra echo.
    Zhuang JJ; Zheng YH; Xu XW; Zhou L
    Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4621-6. PubMed ID: 26698260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Morphological changes in rat substantia nigra induced in vitro by serum from patients with Parkinson's disease.
    Kida E; Renkawek K; Victorov I; Szaszkova N
    Neuropatol Pol; 1986; 24(2):161-8. PubMed ID: 3785686
    [No Abstract]   [Full Text] [Related]  

  • 36. Brain grafting as a treatment for Parkinson's disease.
    Perlow MJ
    Neurosurgery; 1987 Feb; 20(2):335-42. PubMed ID: 3550516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons.
    Tompkins MM; Basgall EJ; Zamrini E; Hill WD
    Am J Pathol; 1997 Jan; 150(1):119-31. PubMed ID: 9006329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progression marker of Parkinson's disease: a 4-year multi-site imaging study.
    Burciu RG; Ofori E; Archer DB; Wu SS; Pasternak O; McFarland NR; Okun MS; Vaillancourt DE
    Brain; 2017 Aug; 140(8):2183-2192. PubMed ID: 28899020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tremor in Parkinson's disease.
    Carr J
    Parkinsonism Relat Disord; 2002 Mar; 8(4):223-34. PubMed ID: 12039416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ageing and Parkinson's disease: why is advancing age the biggest risk factor?
    Reeve A; Simcox E; Turnbull D
    Ageing Res Rev; 2014 Mar; 14(100):19-30. PubMed ID: 24503004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.